WO2018169027A1 - Activateur d'absorption de composé phytochimique - Google Patents

Activateur d'absorption de composé phytochimique Download PDF

Info

Publication number
WO2018169027A1
WO2018169027A1 PCT/JP2018/010366 JP2018010366W WO2018169027A1 WO 2018169027 A1 WO2018169027 A1 WO 2018169027A1 JP 2018010366 W JP2018010366 W JP 2018010366W WO 2018169027 A1 WO2018169027 A1 WO 2018169027A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
phytochemical
yogurt
poorly water
absorption
Prior art date
Application number
PCT/JP2018/010366
Other languages
English (en)
Japanese (ja)
Inventor
雅史 森藤
晶美 北出
深澤　朝幸
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to JP2019506279A priority Critical patent/JP7177039B2/ja
Publication of WO2018169027A1 publication Critical patent/WO2018169027A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Definitions

  • the present invention relates to a phytochemical absorption promoter having an action of promoting absorption of a poorly water-soluble phytochemical into the body.
  • Phytochemicals generally mean plant-derived compounds that are not required for normal physical function maintenance but have a positive effect on health.
  • polyphenol isoflavone is abundant in soybeans and exhibits the functions of menopausal disorder improvement and osteoporosis prevention.
  • Quercetin is abundant in onions and exhibits functions of improving blood flow and reducing body fat.
  • ⁇ -carotene, a terpenoid is abundant in carrots and pumpkins, and functions to maintain visual function, mucous membranes and skin of the body, and immune function, and lycopene is abundant in tomatoes, reducing blood cholesterol and blood pressure. Indicates.
  • Patent Document 1 discloses resveratrol, hesperetin, lacanca (as a catechin absorption promoter) Siraitia grosvenorii extract, jujuba var.inermis extract, citrus aurantiifolia extract, lemon (Citrus limon) extract, pineapple (Ananas comosus) extract, apigenin, glucose, difructose dianhydride III At least one selected from the group consisting of sucralose, aspartame or a salt thereof, erythritol, inositol, citric acid or a salt thereof, phytic acid or a salt thereof, and gallic acid or a salt thereof is disclosed.
  • Patent Document 2 JP-A-2016-93143 discloses the absorption of polyphenols such as catechins and the like into plasma by adding polyphenols such as catechins having low bioavailability to fats and carbohydrates of a specific formulation. There is a disclosure that it is possible to improve the accumulation of.
  • JP-T-2016-506181 discloses a catechin bioavailability enhancer containing cyclodextrin as an active ingredient.
  • Patent Document 4 discloses fermented milk in which about 0.1 to 2,000 ppm of catechins and tocopherols are contained in yogurt containing lactic acid bacteria and bifidobacteria, respectively. It is said that the survivability is improved.
  • Patent Document 5 describes a method for producing a dairy-based nutritional composition having a rich texture and can contain phytochemicals.
  • Patent Document 5 describes a method for producing a dairy-based nutritional composition having a rich texture and can contain phytochemicals.
  • a product of lactic acid bacteria has an action of promoting absorption of phytochemicals.
  • JP 2016-216440 A JP 2016-93143 A Special table 2016-506181 JP-A-8-322464 Special table 2015-527076 gazette
  • the present inventors have now found that lactic acid bacteria products containing polysaccharides significantly increase the uptake of poorly water-soluble phytochemicals into the body, particularly the rate and / or amount of transfer into the blood. It was.
  • the present invention is based on such knowledge.
  • an object of the present invention is to provide a phytochemical absorption promoter having an action of promoting absorption of a poorly water-soluble phytochemical into the body.
  • Another object of the present invention is to provide a food additive comprising the poorly water-soluble phytochemical absorption accelerator, and a food or drink or a food or drink composition to which they are added.
  • the poorly water-soluble phytochemical absorption enhancer according to the present invention comprises a lactic acid bacteria product containing a polysaccharide as an active ingredient.
  • the food additive, food / beverage product or food / beverage product composition according to the present invention comprises the poorly water-soluble phytochemical absorption accelerator according to the present invention.
  • the present invention also relates to a method for promoting the uptake of a poorly water-soluble phytochemical into the human or animal body, which comprises administering or ingesting the lactic acid bacteria product containing the polysaccharide to the human or animal. .
  • the present invention also relates to the use of a lactic acid bacteria product containing a polysaccharide for promoting the incorporation of a poorly water-soluble phytochemical into the human or animal body.
  • the present invention also relates to the use of a lactic acid bacterium product containing a polysaccharide for the production of the poorly water-soluble phytochemical absorption promoter.
  • phytochemical is a natural chemical substance present in plants, a modified product thereof, and a composition containing them, and is not essential for maintaining normal body functions, It means a compound or composition that is or will be ingested as having a positive effect on maintenance and improvement. Therefore, in the present invention, the phytochemical refers to a plant-derived composition in the form of a plant-derived composition containing such a compound as a main component in addition to a plant-derived pure or compound having a certain degree of purity, for example, a fraction. Shall mean.
  • phytochemical means for example, polyphenols, organic sulfur compounds, terpenoids and the like.
  • polyphenols include flavonoids, shigetones, tetraterpenes, and specific examples thereof include flavones (for example, apigenin, luteolin, etc.), isoflavones (for example, apigenin, luteolin, etc.).
  • curcumin is mentioned as a shigeton.
  • organic sulfur compound examples include isocyanates (for example, sulforaphane), cysteine sulfoxides (for example, methylcysteine sulfoxide), and sulfines (for example, allicin).
  • terpenoids include tetraterpenes, and specific examples thereof include carotenoids (for example, ⁇ -carotene, lycopene, lutein, astaxanthin, etc.).
  • carotenoids for example, ⁇ -carotene, lycopene, lutein, astaxanthin, etc.
  • the phytochemical includes those analogs, and preferred examples thereof include glucoside (genistin) and conjugate (glucuronic acid conjugate, sulfate conjugate) for genistin, and quercetin.
  • glucoside genistin
  • conjugate glucuronic acid conjugate, sulfate conjugate
  • quercetin quercetin.
  • conjugate glucuronic acid conjugate, sulfate conjugate
  • kaempferol glycoside (hesperidin)
  • conjugate glucuronic acid conjugate, Sulfate conjugates
  • epicatechin and catechin isomers (catechin), polymers (procyanidin B1, procyanidin B2, procyanidin B5, procyanidin C1, etc.), conjugates (glucuronic acid conjugates, sulfate conjugates) and gallic esters (epicatechin gallate) , Epigallocatechin gallate).
  • hesperetin include glycosides (hesperidin) and conjugates (glucuronic acid conjugates, sulfate conjugates), and naringenin includes glycosides (naringenin) and conjugates (glucuronic acid conjugates, sulfate conjugates).
  • ⁇ -carotene isomers ( ⁇ -carotene, ⁇ -carotene) and metabolites (retinol palmitate, apo-10-carotenal, retinol) and metabolites (apo-10-lycopenal) for lycopene are included.
  • phytochemicals include plant-derived extracts and concentrates.
  • Preferred examples include genistein extracts and concentrates derived from soybeans, red beans, peas and empty beans, quercetin extracts and concentrates derived from onions and apples, and kaempferol derived from tea and broccoli.
  • the extract and concentrate of origin are mentioned.
  • the phytochemical is sparingly water-soluble.
  • the poorly water-soluble phytochemical is one having a water solubility of 88% or less, more preferably 50% or less, more preferably 20% or less, and most preferably 1. % Phytochemical.
  • the “dissolution rate” in the present invention is an index representing the ease of dissolution of the compound in water, and the concentration of the supernatant after centrifugation after dissolving the compound in pure water by shaking. The value obtained by dividing (w / v) by the concentration (w / v) before dissolution by shaking is shown as a percentage (%). The concentration can be measured using a spectrophotometer.
  • a solution prepared by adding 33.3 mg of the phytochemical compound to 10 mL of pure water is preferably used for measuring the “dissolution rate”.
  • the “dissolution rate” may be measured using a solution prepared by adding 3.3 mg to 10 mL of pure water.
  • the temperature condition for measuring the “dissolution rate” is 21 ⁇ 2 ° C.
  • the poor water solubility of phytochemicals is determined by the “concentration (w / v) of supernatant obtained by dissolving the compound by shaking in pure water and then centrifuging” obtained in the measurement of the “dissolution rate”.
  • the dissolution rate in water of 88% or less corresponds to 293 mg / 100 g or less.
  • the absorption promotion of phytochemical refers to the rate of phytochemical uptake into the body, particularly the transfer to the blood, compared to a control ingested without lactic acid bacteria products containing polysaccharides. And / or means significantly increasing the amount of migration. Specifically, after administration, this means either or both of producing a high blood concentration compared to the control or a large blood concentration-time curve area (AUC) compared to the control. To do. Thereby, the effect of phytochemical intake can be obtained in a smaller amount or in a shorter time, and the raw material cost can be reduced. Moreover, by adding the phytochemical absorption promoter according to the present invention to foods and drinks and food and drink compositions, it is possible to increase the added value of food and drinks and increase the commercial value.
  • lactic acid bacteria producing organisms present invention containing polysaccharide
  • a "lactic acid bacteria producing organism” containing polysaccharide in addition to the lactic acid bacteria fermentation product, lactic acid bacteria culture, the lactic acid bacteria metabolites like, to containing polysaccharides by fermentation of lactic acid bacteria Is broadly meant.
  • the “polysaccharide” is a sugar chain polymer composed of sugars such as galactose, glucose, rhamnose, mannose, N-acetylglucosamine.
  • the polysaccharides may include acidic polysaccharides to which phosphate groups are bonded.
  • the molecular weight is usually in the range of 5000 to 500,000.
  • lactic acid bacteria is a general term for microorganisms that assimilate glucose and produce lactic acid with a yield of sugar of 50% or more. It has characteristics such as no sex, no sporulation ability, and catalase negative. Lactic acid bacteria have been eaten all over the world through fermented milk since ancient times, and can be said to be extremely safe microorganisms.
  • lactic acid bacteria have been genus Lactococcus, Lactobacillus, Leuconostoc, Pediococcus, Streptococcus, Wissella, Tetrageno
  • the genus is classified into 11 genera such as Tetragenococcus genus, Oenococcus genus, Enterococcus genus, Vagococcus genus and Carnobacterium genus. In the embodiment of the present invention, all these lactic acid bacteria can be used.
  • Lactobacillus delbruecki subspecies bulgaricus Using Lactobacillus delbruecki subspecies bulgaricus OLL1247 or Lactobacillus delbrucky subspecies bulgaricus OLL1224, As Streptococcus thermophilus, Streptococcus thermophilus OLS3078 or Streptococcus thermophilus OLS3290 is used.
  • Lactobacillus delbruecki subspecies bulgaricus OLLG1247 is dated March 6, 2014 (consignment date), and is the Patent Evaluation Microorganism Depositary Center for Product Evaluation Technology (Kazusa, Kisarazu, Chiba, Japan). It is deposited internationally under the Budapest Treaty under the accession number NITE BP-01814.
  • Lactobacillus delbruecki subspecies bulgaricus OLL 1224 bacteria was issued on July 2, 2009 (contract date) as the accession number NITE BP-778 to the Patent Microorganism Depositary of the National Institute of Technology and Evaluation of the National Institute of Technology and Evaluation. Deposited internationally under the Budapest Treaty.
  • Streptococcus thermophilus OLS3078 was deposited internationally under the Budapest Treaty as a deposit number NITE BP-01697, on August 23, 2013 (date of trust), to the National Institute of Technology and Evaluation of the National Institute of Technology and Evaluation, with the accession number NITE BP-01697. ing.
  • Streptococcus thermophilus OLS3290 was internationally deposited under the Budapest Treaty on January 19, 2004 (consignment date), under the accession number FERM BP-19638, to the National Institute of Technology and Technology Patent Microorganisms Deposited Microorganisms. Yes.
  • the “fermented product of lactic acid bacteria” means a culture obtained by fermentation with lactic acid bacteria, a composition comprising the same, and a composition after treatment. Therefore, the fermented lactic acid bacteria include a fermented lactic acid bacterium and a processed product thereof, for example, a culture filtrate or culture supernatant obtained by sterilizing a culture (fermented lactic acid bacterium) by filtration, centrifugation, membrane separation, or the like. Liquid, culture filtrate / culture supernatant, lactic acid bacteria fermentation product, and the like concentrated by an evaporator or the like, pasted product, diluted product, or dried product (for example, frozen, heated, reduced pressure, etc.).
  • the treatment can be carried out by combining one or more of the above treatment steps such as sterilization treatment such as filtration, centrifugation, membrane separation, precipitation, concentration, pasting, dilution, drying and the like.
  • sterilization treatment such as filtration, centrifugation, membrane separation, precipitation, concentration, pasting, dilution, drying and the like.
  • examples of the culture medium include nonfat dry milk medium and MRS medium to which yeast extract is added.
  • the lactic acid bacteria product is particularly preferably a milk fermentation product, a milk culture, or a milk metabolite of lactic acid bacteria.
  • the fermented milk product, the milk culture product, and the milk metabolite include fermented milk (yogurt).
  • fermented milk can be preferably used as its supernatant.
  • the fermented milk may contain a thickener and a gelling agent such as pectin, guar gum, xanthan gum, carrageenan, and processed starch, in addition to a culture solution such as skim milk powder and a whey degradation product.
  • examples of the milk include animal milk such as cow milk and processed products thereof (for example, skim milk, whole milk powder, skim milk powder, spinach milk, casein, whey, fresh cream, compound cream, butter, butter Milk powder, cheese, etc.) and vegetable milk such as soybean milk derived from soybeans.
  • animal milk such as cow milk and processed products thereof (for example, skim milk, whole milk powder, skim milk powder, spinach milk, casein, whey, fresh cream, compound cream, butter, butter Milk powder, cheese, etc.)
  • vegetable milk such as soybean milk derived from soybeans.
  • the milk may be sterilized or may not be sterilized.
  • a fermented milk raw material mix can be used as a raw material for fermented milk (yogurt).
  • the fermented milk raw material mix is a mixture containing raw milk and other components.
  • This fermented milk raw material mix includes raw materials commonly used in the production of fermented milk such as raw milk, water, and other optional components (eg, sugar, sugar, sweetener, sour agent, mineral, vitamin, flavor, etc.). It is obtained by warming to dissolve and mixing.
  • Raw milk may contain water, raw milk, pasteurized milk, skim milk, whole milk powder, skim milk powder, whole fat concentrated milk, skim concentrated milk, butter milk, butter, cream, cheese, and the like.
  • the raw milk may contain whey protein concentrate (WPC), whey protein isolate (WPI), ⁇ -lactalbumin ( ⁇ -La), ⁇ -lactoglobulin ( ⁇ -Lg) and the like. .
  • fermented milk may be prepared by a method commonly used in the art. That is, fermented milk (yogurt) is manufactured through processes such as a raw material mix preparation process, a raw material mix (heating) sterilization process, a raw material mix cooling process, a starter addition process, a fermentation process, and a fermented milk cooling process. It's okay. Moreover, you may employ
  • a medium for culturing lactic acid bacteria a medium usually used in the art for culturing lactic acid bacteria can be used. That is, any medium can be used as long as it contains a nitrogen source, an inorganic substance and other nutrients in addition to the main carbon source.
  • a nitrogen source lactose, glucose, sucrose, fructose, starch hydrolysate, molasses, etc. can be used depending on the assimilation ability of the bacteria used.
  • organic nitrogen-containing substances such as casein hydrolyzate, whey protein hydrolyzate, ⁇ -lactalbumin, ⁇ -lactoglobulin, glycomacropeptide, soybean protein hydrolyzate and the like can be used.
  • meat extract, fish extract, yeast extract and the like can be used as the growth promoter.
  • lactic acid bacteria may be cultured in an anaerobic state, or may be cultured in a microaerobic state used in liquid stationary culture or the like.
  • a culture method under anaerobic conditions for example, a known method such as a method of culturing in a carbon gas gas phase can be adopted, but other methods may be adopted.
  • the culture temperature is preferably in the range of 30 ° C. to 47 ° C., more preferably in the range of 35 ° C. to 46 ° C., and still more preferably in the range of 37 ° C. to 45 ° C. .
  • the pH of the medium during the cultivation of lactic acid bacteria is preferably maintained within the range of 6 or more and 7 or less, but may be other pH ranges as long as the pH allows the bacteria to grow.
  • the culture time for lactic acid bacteria and the like is usually preferably in the range of 1 hour to 48 hours, more preferably in the range of 1.5 hours to 36 hours, and more preferably in the range of 2 hours to 24 hours. More preferably it is.
  • the fermented milk typically has a solid content of non-fat milk of 8% by weight or more, and the number of lactic acid bacteria or yeast is 10 6 / ml or more and 10 11 / Ml or less.
  • “absorption enhancer” is used in the form of lactic acid bacteria fermentation product, lactic acid bacteria culture, lactic acid bacteria metabolite, etc. as “lactic acid bacteria product”. However, it is preferably used after being formulated. Therefore, in the present invention, the “absorption enhancer” includes, for example, pharmaceuticals, as well as those provided in the form of preparations that are ingested as they are, preferably taken orally, so-called supplements, and as food additives. Also included are those that are added to other foods and foods and used to add a phytochemical absorption promoting action to the foods and foods.
  • the food / beverage products which comprise the phytochemical absorption promoter by this invention, the processed food / beverage products, and the food / beverage product composition are also included by this invention.
  • a preparation is a preparation prepared in accordance with a conventional method, preferably an oral preparation, in combination with additives that are acceptable for formulation.
  • This preparation may take the form of solid preparations such as tablets, powders, fine granules, granules, capsules, pills, sustained-release preparations, and liquid preparations such as solutions, suspensions and emulsions.
  • Additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, fragrances, buffers, antioxidants, pH Examples thereof include regulators.
  • Specific examples of food additives include seasonings such as processed seasonings, flavor seasonings, and cooking mixes.
  • the food and drink and the food and drink composition are processed for human and animal food and drink, and are orally used as solutions, suspensions, emulsions, powders, solid molded articles, and the like. There is no particular limitation as long as it is an ingestible form.
  • foods and drinks and food and drink compositions include milk products (including processed milk), yogurts, lactic acid bacteria beverages, fermented milk, ice creams, creams, cheeses, and other dairy products; Beverages, fruit juice drinks, vegetable drinks, soy milk drinks, coffee drinks, tea drinks, jelly drinks, nutrition drinks, cosmetic drinks, powdered drinks such as cocoa and smoothies, sports powder drinks, nutrition-enriched powder drinks, cosmetic powders Beverages such as food, powdered soup, steamed bread, concentrated beverages, alcoholic beverages; flour products such as bread, pasta, noodles, cake mix, fried flour, bread crumbs; chocolate, gum, candy, cookies, gummi, Confectionery such as snacks, Japanese confectionery, jelly, pudding dessert confectionery; curry, pasta sauce, potov, stew, Japanese-style food retort food; -Fats and oils such as margarine, spread and mayonnaise; Instant foods such as freeze-dried foods; Agricultural processed products such as canned agricultural products, jam marmalades, pickles, boiled beans,
  • the food and drink and the food and drink composition include functional food, health nutrition food, health food, food for specified health use, functional indication food, nutrition functional food, food for the sick, infant formula, pregnant woman Or the thing of classification
  • marker is included.
  • the indication of disease risk reduction is the indication of food or drink that may reduce the disease risk, and is based on the standard established by the FAO / WHO Joint Food Standards Committee (Codex Committee) or Refers to the standard and is a prescribed or recognized indication.
  • arbitrary components can be added to the food and drink and the food and drink composition as necessary.
  • optional ingredients are not particularly limited, but are usually sweeteners, acidulants, vegetables, fruits and seed juices and extracts, vitamins, minerals, amino acids, etc.
  • Nutrients lactic acid bacteria (excluding essential lactic acid bacteria according to embodiments of the present invention), useful microorganisms such as bifidobacteria and propionic acid bacteria, fermented products thereof, functional sugars such as oligosaccharides, royal jelly, glucosamine , Existing functional materials such as astaxanthin, collagen, polyphenol, fragrance, pH adjuster, excipient, acidulant, colorant, emulsifier, preservative and the like.
  • a lactic acid bacteria product containing a polysaccharide for the production of the poorly water-soluble phytochemical absorption enhancer according to the present invention described above. Is done.
  • the intake amount of the phytochemical absorption enhancer may be appropriately determined.
  • the intake amount of the polysaccharide is 200 ⁇ g or more / day.
  • the amount is preferably in the range of 200 ⁇ g / day to 60000 ⁇ g / day, more preferably in the range of 300 ⁇ g / day to 45000 ⁇ g / day, and more preferably in the range of 400 ⁇ g / day to 30000 ⁇ g / day.
  • the period of ingestion is not particularly limited, but it is preferable to ingest at least once, for example.
  • the required dose can be converted from the required dose in animal experiments (eg, mouse experiments) to the required dose to the human body using the following formula based on Food Safety Commission data.
  • (Necessary administration dose to human body (converted value)) (Necessary administration dose to animal) ⁇ (Lower female body weight: 40 kg) ⁇ (Safety factor: 100)
  • poorly water-soluble in the human or animal body comprising administering or ingesting a lactic acid bacteria product containing a polysaccharide to a human or animal.
  • a method for promoting uptake of sex phytochemicals is provided.
  • use of a lactic acid bacteria product containing a polysaccharide to promote uptake of a poorly water-soluble phytochemical into the human or animal body.
  • quercetin group a group of rats administered with quercetin (control)
  • quercetin + yogurt group a group of rats administered with quercetin + yogurt
  • quercetin metabolite quercetin conjugate and isorhamnetin conjugate were measured as follows. Glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) is dissolved in 45 ⁇ L (10000 U / mL, Sigma-Aldrich) and 0.1 M sodium acetate buffer (pH 5.0) in 50 ⁇ L of serum. 5 ⁇ L of 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 ⁇ L of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 ⁇ L of a 50% acetonitrile solution containing 0.1% formic acid.
  • MS / MS analysis was performed in ESI negative mode.
  • the MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of ⁇ 4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.
  • FIG. 1 is a graph showing the serum concentration of quercetin conjugate
  • FIG. 2 is a graph showing the serum concentration of isorhamnetin conjugate.
  • the serum concentrations of the quercetin conjugate and the isorhamnetin conjugate were significantly increased in the quercetin + yogurt group as compared to the quercetin group.
  • the area under the blood concentration-time curve (AUC) was significantly increased in the quercetin + yogurt group as compared to the quercetin group. This result means that ingestion of yogurt promotes absorption of quercetin.
  • the symbol “*” indicates that there is a significant difference with respect to the quercetin group at P ⁇ 0.05.
  • Experimental Example 2 Enhancement of absorption of quercetin (Part 2) (1) Used skim milk powder and yoghurt The culture medium used in Experimental Example 1 (1) as skim milk powder was used, and the yoghurt prepared in Experimental Example 1 was used as yoghurt.
  • FIG. 3 is a graph showing the serum concentration of quercetin conjugate
  • FIG. 4 is a graph showing the serum concentration of isorhamnetin conjugate.
  • the serum concentration of the quercetin metabolite at 60 minutes and 120 minutes after administration, and the isorhamnetin conjugate at 60 minutes, 120 minutes, and 240 minutes after administration were significantly increased in the quercetin + skim milk group.
  • serum concentrations of quercetin metabolites or isorhamnetin conjugates increased.
  • the area under the blood concentration-time curve (AUC) of the quercetin conjugate was significantly increased in the quercetin + yogurt group as compared to the quercetin + fat dry milk group. This result means that fermentation by lactic acid bacteria promotes absorption of quercetin.
  • the symbol “*” indicates that there is a significant difference with respect to the quercetin + fat dry milk group at P ⁇ 0.05.
  • quercetin group the group of rats administered with quercetin (control) is referred to as “quercetin group”
  • quercetin polysaccharide concentrate group the group of rats administered with quercetin polysaccharide concentrate (Example) is referred to as “quercetin + polysaccharide concentrate group”.
  • FIG. 5 is a graph showing the serum concentration of quercetin conjugate
  • FIG. 6 is a graph showing the serum concentration of isorhamnetin conjugate.
  • the serum concentration of the quercetin conjugate was 480 minutes after administration
  • the serum concentration of the isorhamnetin conjugate was 240 minutes and 480 minutes after administration.
  • serum concentrations of quercetin metabolites or isorhamnetin conjugates increased.
  • the area under the blood concentration-time curve (AUC) of the isorhamnetin conjugate was significantly increased in the quercetin + polysaccharide concentrate group compared to the quercetin group.
  • AUC blood concentration-time curve
  • Experimental Example 4 Enhanced absorption of genistein (1) Yogurt used The yogurt prepared in Experimental Example 1 was used.
  • genistein group a group of rats administered with genistein (control)
  • genistein + yogurt group a group of rats administered with genistein + yogurt
  • the genistein conjugate which is a genistein metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 ⁇ L of serum was added to 45 ⁇ L (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 ⁇ L of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 ⁇ L of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 ⁇ L of a 50% acetonitrile solution containing 0.1% formic acid.
  • MS / MS analysis was performed in ESI negative mode.
  • the MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of ⁇ 4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.
  • Results were as shown in Table 4 and FIG.
  • the serum concentration of genistein conjugate was significantly increased in the genistein + yogurt group as compared to the genistein group.
  • serum concentrations of genistein conjugates increased.
  • the area under the blood concentration-time curve (AUC) was significantly increased in the genistein + yogurt group as compared to the genistein group. This result means that intake of yogurt promotes genistein absorption.
  • the symbol “*” indicates that there is a significant difference with respect to the genistein group at P ⁇ 0.05.
  • Experimental Example 5 Absorption promotion of epicatechin (part 1) (1) Yogurt used The yogurt prepared in Experimental Example 1 was used.
  • epicatechin group a group of rats administered with epicatechin (control)
  • epicatechin + yogurt group a group of rats administered with epicatechin and yogurt (Example)
  • epicatechin + yogurt group a group of rats administered with epicatechin + yogurt
  • the epicatechin conjugate which is an epicatechin metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 ⁇ L of serum was added to 45 ⁇ L (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 ⁇ L of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 ⁇ L of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 ⁇ L of a 50% methanol solution containing 0.1% formic acid.
  • MS / MS analysis was performed in ESI negative mode.
  • the MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of ⁇ 4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.
  • ⁇ -carotene group a group of rats administered with ⁇ -carotene (control)
  • ⁇ -carotene + yogurt group a group of rats administered with ⁇ -carotene and yogurt
  • ⁇ -carotene + yogurt group a group of rats administered with ⁇ -carotene and yogurt
  • Experimental Example 7 Promotion of ⁇ -carotene absorption (Part 2) (1) Used skim milk powder and yoghurt The culture medium used in Experimental Example 1 (1) as skim milk powder was used, and the yoghurt prepared in Experimental Example 1 was used as yoghurt.
  • ⁇ -carotene + fat dry milk group a group of rats administered with ⁇ -carotene and yogurt (Example) is designated as “ ⁇ -carotene + It will be called "yogurt group”.
  • Experimental Example 8 Promotion of ⁇ -carotene absorption (Part 3) (1) Polysaccharide concentrate used The polysaccharide concentrate prepared in Experimental Example 3 was used.
  • ⁇ -carotene group a group of rats administered with ⁇ -carotene (control)
  • ⁇ -carotene group a group of rats administered with ⁇ -carotene and a polysaccharide concentrate (Example) is designated as “ ⁇ -carotene + polysaccharide concentrate”. It will be called a “group of things”.
  • Experimental example 9 absorption enhancement of lycopene (part 1)
  • Yogurt used The yogurt prepared in Experimental Example 1 was used.
  • lycopene was administered at 5 mg / kg body weight
  • yogurt was administered at 11.3 g / kg body weight. Blood was collected from the abdominal vena cava 120 minutes after administration to obtain serum.
  • lycopene group a group of rats administered with lycopene (control)
  • lycopene + yogurt group a group of rats administered with lycopene + yogurt
  • ⁇ G rutin group the rat group (control) administered with ⁇ -glucosyl rutin
  • ⁇ G rutin + yogurt group the rat group (Example) administered with ⁇ -glucosyl rutin and yogurt
  • FIG. 12 is a graph showing the serum concentration of quercetin conjugate
  • FIG. 13 is a graph showing the serum concentration of isorhamnetin conjugate.
  • AUC area under the blood concentration-time curve
  • Experimental example 10 Solubility of phytochemical (1) Experimental method Epicatechin (manufactured by Sigma Aldrich), catechin (manufactured by Tokyo Chemical Industry Co., Ltd.), quercetin (manufactured by Wako Pure Chemical Industries, Ltd.), genistein (Tokyo Chemical Industry Co., Ltd.) Company), rutin (manufactured by Wako Pure Chemical Industries, Ltd.), ⁇ -glucosyl rutin (manufactured by Wako Pure Chemical Industries, Ltd.), hesperidin (manufactured by Wako Pure Chemical Industries, Ltd.), naringin (manufactured by Sigma Aldrich), naringenin (Sigma) Aldrich), kaempferol (Extra Synthase), ⁇ -carotene (Wako Pure Chemical Industries), and lycopene (Wako Pure Chemical Industries) were used.
  • epicatechin, catechin, quercetin, genistein, naringenin, kaempferol, and luteolin were each added to 33.3 mg with 10 mL of ultrapure water.
  • the phytochemical of the glycoside is 67.3 mg (33.3 mg as quercetin) of rutin, so that the amount of aglycon (part other than the carbohydrate obtained by hydrolyzing the glycoside) is 33.3 mg, ⁇ -glucosyl 10 mL of ultrapure water was added to 89.6 mg of rutin (33.3 mg as quercetin), 67.3 mg of hesperidin (33.3 mg as hesperetin), 71.0 mg of naringin (33.3 mg as naringenin).
  • the terpenoid was added with ⁇ -carotene and lycopene to 3.3 mg each and 10 mL of ultrapure water.
  • the prepared solution was shaken for 3 hours and then centrifuged at 2000 ⁇ g for 10 minutes.
  • the centrifugal supernatant was filtered using a 0.45 ⁇ L filter.
  • Absorbance of the centrifugal supernatant epicatechin, catechin, hesperidin, naringin, naringenin is 280 nm, genistein is 260 nm, quercetin, rutin, ⁇ -glucosylrutin, kaempferol is 360 nm, ⁇ -carotene is 450 nm, lycopene is 470 nm, spectrophotometer was measured.
  • Dissolution rate (%) ((concentration of centrifugal supernatant after shaking dissolution (w / v) ⁇ (concentration of solution before shaking dissolution (w / v))) ⁇ 100
  • Experimental Example 11 Promotion of Luteolin Absorption (1) Yogurt Used The yogurt prepared in Experimental Example 1 was used.
  • luteoline group a group of rats administered with luteolin (control)
  • luteoline + yogurt group a group of rats administered with luteolin and yogurt
  • the luteolin conjugate which is a luteolin metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 ⁇ L of serum was added to 45 ⁇ L (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 ⁇ L of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 ⁇ L of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 ⁇ L of a 50% acetonitrile solution containing 0.1% formic acid.
  • MS / MS analysis was performed in ESI negative mode.
  • the MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of ⁇ 4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.
  • Experimental example 12 Promotion of absorption of naringenin (1) Yogurt used The yogurt prepared in Experimental example 1 was used.
  • naringenin group a group of rats administered with naringenin (control)
  • naringenin + yogurt group a group of rats administered with naringenin and yogurt
  • Naringenin conjugate which is a naringenin metabolite was measured as follows. That is, a glucuronidase solution dissolved in 0.1 M sodium acetate buffer (pH 5.0) in 45 ⁇ L of serum was added to 45 ⁇ L (10000 U / mL, manufactured by Sigma-Aldrich), and 0.1 M sodium acetate buffer (pH 5.0). 5 ⁇ L of the dissolved 0.1 M ascorbic acid solution was added and heated at 37 ° C. for 2 hours. 300 ⁇ L of methanol was added to stop the enzyme reaction, followed by centrifugation (12000 rpm, 10 minutes, 4 ° C.). The supernatant was transferred to another tube, and the solvent was removed by centrifugal concentration. A sample for HPLC was prepared by dissolving in 300 ⁇ L of a 50% acetonitrile solution containing 0.1% formic acid.
  • MS / MS analysis was performed in ESI negative mode.
  • the MS / MS analysis conditions were set to a curtain gas flow rate of 30 psi, a collision gas flow rate of 9 psi, an ion spray voltage of ⁇ 4500 V, a turbo gas temperature of 600 ° C., and an ion source gas of 70 psi.
  • Results were as shown in Table 14 and FIG.
  • the serum concentration of naringenin conjugate was significantly increased in the naringenin + yogurt group compared to the naringenin group.
  • serum concentrations of naringenin conjugates increased.
  • the area under the blood concentration-time curve (AUC) was significantly increased in the naringenin + yogurt group as compared to the naringenin group. This result means that ingestion of yogurt promotes absorption of naringenin.
  • the symbol “*” indicates that there is a significant difference with respect to the naringenin group at P ⁇ 0.05.
  • lycopene group a group of rats administered with lycopene (control)
  • lycopene + yogurt group a group of rats administered with lycopene + yogurt
  • ⁇ -carotene group a group of rats administered with ⁇ -carotene (control)
  • ⁇ -carotene + OLL1224 group a group of rats (Example) administered with ⁇ -carotene and yogurt
  • ⁇ -carotene + OLL1247 group A group of rats (Example) administered with ⁇ -carotene and yogurt (Lactobacillus bulgaricus OLL1247) is referred to as “ ⁇ -carotene + OLL1247 group”.
  • ⁇ -carotene group a group of rats administered with ⁇ -carotene (control) is referred to as a “ ⁇ -carotene group”, and a group of rats administered with ⁇ -carotene and yogurt (Streptococcus thermophilus OLS3290) (Examples) is designated as “ ⁇ -carotene + OLS3290 group”, ⁇ A group of rats (Example) administered with carotene and yogurt (Streptococcus thermophilus OLS3078) will be referred to as “ ⁇ -carotene + OLS3078 group”.
  • the serum concentration of ⁇ -carotene was measured according to the method and conditions described in Experimental Example 6.
  • the group of rats administered with ⁇ -carotene (control) is referred to as “ ⁇ -carotene group”
  • the group of rats administered with ⁇ -carotene and yogurt (Caspian Sea yogurt) (Example) is “ ⁇ -carotene + Caspian Sea YG group”.
  • a group of rats (Example) administered with ⁇ -carotene and yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) will be referred to as “ ⁇ -carotene + OLL1247 ⁇ OLS3078”.
  • Results were as shown in Table 18.
  • the area under the blood concentration-time curve (AUC) was significantly increased in the ⁇ -carotene + OLL1247 ⁇ OLS3078 group compared to the ⁇ -carotene group. This result means that ingestion of yogurt promotes the absorption of ⁇ -carotene.
  • the group of rats administered with quercetin is referred to as “quercetin group”, and the group of rats administered with quercetin and yogurt (Lactobacillus bulgaricus 2038 and Streptococcus thermophilus 1131) (Example) is designated as “quercetin + LB81”.
  • Group ” a group of rats (Example) administered with quercetin and yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) will be referred to as“ Quercetin + OLL1247 ⁇ OLL3078 ”.
  • Experimental Example 18 Absorption promotion of epicatechin (part 2) (1) Yogurt used The yogurt prepared in Experimental Example 1 was used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dairy Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

L'invention concerne un activateur d'absorption de composé phytochimique difficilement soluble dans l'eau capable d'augmenter significativement la vitesse et/ou la quantité d'absorption d'un composé phytochimique dans le corps, en particulier sa transition dans le sang. Un produit de lactobacille contenant un polysaccharide peut augmenter significativement la vitesse et/ou la quantité d'absorption d'un composé phytochimique dans le corps, en particulier sa transition dans le sang. Par conséquent, l'activateur d'absorption de composé phytochimique selon la présente invention comprend le produit de lactobacille en tant que principe actif. De plus, l'activateur d'absorption de composé phytochimique est utile en tant qu'additif alimentaire. En ajoutant l'activateur d'absorption de composé phytochimique à un aliment, une boisson ou une composition d'aliment ou de boisson, un effet d'activation de l'absorption de composé phytochimique peut lui être conféré.
PCT/JP2018/010366 2017-03-16 2018-03-16 Activateur d'absorption de composé phytochimique WO2018169027A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019506279A JP7177039B2 (ja) 2017-03-16 2018-03-16 フィトケミカル吸収促進剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-051965 2017-03-16
JP2017051965 2017-03-16

Publications (1)

Publication Number Publication Date
WO2018169027A1 true WO2018169027A1 (fr) 2018-09-20

Family

ID=63522302

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/010366 WO2018169027A1 (fr) 2017-03-16 2018-03-16 Activateur d'absorption de composé phytochimique

Country Status (2)

Country Link
JP (1) JP7177039B2 (fr)
WO (1) WO2018169027A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020032100A1 (fr) * 2018-08-08 2020-02-13 株式会社明治 Composition favorisant l'absorption de substances phytochimiques
CN111466439A (zh) * 2019-01-24 2020-07-31 株式会社明治 具有血糖值上升抑制作用的发酵乳
WO2022158595A1 (fr) * 2021-01-25 2022-07-28 フジッコ株式会社 Promoteur d'absorption des isoflavones et inhibiteur de réduction de l'humidité de la peau

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08322464A (ja) * 1995-05-26 1996-12-10 Yakult Honsha Co Ltd ビフィドバクテリウム菌を含有するヨーグルト及びその製造法
WO2016111276A1 (fr) * 2015-01-06 2016-07-14 株式会社明治 Promoteur d'absorption de sphingolipides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08322464A (ja) * 1995-05-26 1996-12-10 Yakult Honsha Co Ltd ビフィドバクテリウム菌を含有するヨーグルト及びその製造法
WO2016111276A1 (fr) * 2015-01-06 2016-07-14 株式会社明治 Promoteur d'absorption de sphingolipides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HERBERT, MICHLMAYR ET AL.: "beta -Glucosidase activities of lactic acid bacteria:mechanisms, impact on fermented food and human health", FEMS MICROBIOL. LETT., vol. 352, 2014, pages 1 - 10, XP055608866 *
KANO, MITSUYOSHI ET AL.: "Bioavailability of Isoflavones after Ingestion of Soy Beverages in Healthy Adults", THE JOURNAL OF NUTRITION, vol. 136, 2006, pages 2291 - 2296, XP055608861 *
TAMURA, MOTOI ET AL.: "Role of Intestinal Flora on the Metabolism, Absorption, and Biological Activity of Dietary Flavonoids", BIOSCIENCE MICROFLORA, vol. 22, no. 4, 2003, pages 125 - 131, XP055608868 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020032100A1 (fr) * 2018-08-08 2020-02-13 株式会社明治 Composition favorisant l'absorption de substances phytochimiques
CN111466439A (zh) * 2019-01-24 2020-07-31 株式会社明治 具有血糖值上升抑制作用的发酵乳
JP2020115783A (ja) * 2019-01-24 2020-08-06 株式会社明治 血糖値上昇抑制作用を有する発酵乳
JP7267020B2 (ja) 2019-01-24 2023-05-01 株式会社明治 血糖値上昇抑制作用を有する発酵乳
WO2022158595A1 (fr) * 2021-01-25 2022-07-28 フジッコ株式会社 Promoteur d'absorption des isoflavones et inhibiteur de réduction de l'humidité de la peau
JP7166500B1 (ja) * 2021-01-25 2022-11-07 フジッコ株式会社 イソフラボン吸収促進剤及び皮膚水分量低下抑制剤

Also Published As

Publication number Publication date
JP7177039B2 (ja) 2022-11-22
JPWO2018169027A1 (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
CN103987278A (zh) 营养性的植物营养素组合物
JP2016515398A (ja) 常温保存可能な発酵乳製品及びそれを製造する方法
TW201215331A (en) Nutritional products having improved organoleptic properties
JP2008148588A (ja) ポリフェノール組成物
JP7177039B2 (ja) フィトケミカル吸収促進剤
EP2753612A1 (fr) Obtention de produits enrichis
Lisak et al. Sensory evaluation of the strawberry flavored yoghurt with stevia and sucrose addition
WO2019027725A1 (fr) Compositions nutritionnelles liquides comprenant un extrait de thé vert et du fer
BR112018076294B1 (pt) Bebida ou composição, método para modificar as características sensoriais de uma composição, e, produto alimentício
US20150173386A1 (en) Acid whey-based compositions
US20230241137A1 (en) Composition for promoting absorption of phytochemicals
KR100998575B1 (ko) 김치유산균으로 발효한, 콩요구르트(쏘이프로)와 식물추출발효액(면역유산효소)을 함유하는 의약품 및 건강기능식품의 제조방법
CN109259225A (zh) 低缓冲营养组合物及其用途
CN107106618A (zh) 鞘脂吸收促进剂
EP2432485B1 (fr) Composition prébiotique
KR102538090B1 (ko) 단백질 분해능을 가지는 락토바실러스 카제이 idcc 3451을 포함하는 식품 조성물 및 건강기능식품
CN104023559B (zh) 用于代谢程序化作用的植物营养素的组合物和方法
KR102423025B1 (ko) 단백질 분해능을 가지는 락토바실러스 람노서스 idcc 3201을 포함하는 식품 조성물 및 건강기능식품
JP2005097168A (ja) 整腸用組成物
JP2005124540A (ja) ポリフェノール組成物
JP6849890B2 (ja) デオキシリボ核酸保存用組成物およびその製造方法、デオキシリボ核酸を保存する方法、乳酸菌産生物およびその使用方法
WO2023068374A1 (fr) Composition pour favoriser l'assimilation d'un oligosaccharide
Anastasova et al. Concepts, benefits and perspectives of functional dairy food products
KR20170087397A (ko) 유아 분변에서 분리한 균주 및 이를 이용한 항산화 기능을 갖는 발효유의 제조방법
JP2001333692A (ja) 発酵豆乳の製造方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18767411

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019506279

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18767411

Country of ref document: EP

Kind code of ref document: A1